{
    "root": "126a781e-e59f-4108-b897-362759588bf6",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KADCYLA",
    "value": "20250519",
    "ingredients": [
        {
            "name": "TRASTUZUMAB EMTANSINE",
            "code": "SE2KH7T06F",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_231601"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17992"
        },
        {
            "name": "SUCCINIC ACID",
            "code": "AB6MNQ6J6L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15741"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "POLYSORBATE 20",
            "code": "7T1F30V5YH",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_53424"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        }
    ],
    "indications": {
        "text": "kadcyla her2-targeted antibody microtubule inhibitor conjugate indicated , single agent , : treatment patients her2-positive , metastatic breast cancer previously received trastuzumab taxane , separately combination . patients either : received prior therapy metastatic disease , developed disease recurrence within six months completing adjuvant therapy . ( 1.1 ) adjuvant treatment patients her2-positive early breast cancer residual invasive disease neoadjuvant taxane trastuzumab-based treatment . ( 1.2 ) select patients therapy based fda-approved companion diagnostic kadcyla [ ( 2.1 ) ]",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "substitute kadcyla trastuzumab . her2 testing : perform using fda-approved tests laboratories demonstrated proficiency . ( 2.1 ) intravenous infusion . administer intravenous push bolus . dextrose ( 5 % ) solution . ( 2.4 ) recommended dose kadcyla 3.6 mg/kg given intravenous infusion every 3 weeks ( 21-day cycle ) disease progression unacceptable toxicity , total 14 cycles patients ebc . administer kadcyla doses greater 3.6 mg/kg . ( 2.2 ) management ( infusion-related , hepatotoxicity , left ventricular cardiac dysfunction , thrombocytopenia , pulmonary toxicity peripheral neuropathy ) may require temporary interruption , dose reduction , treatment discontinuation kadcyla . ( 2.3 )",
        "doid_entities": [
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "thrombocytopenia (DOID:1588)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1588"
            },
            {
                "text": "peripheral neuropathy (DOID:574)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_574"
            },
            {
                "text": "neuropathy (DOID:870)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_870"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "KADCYLA is a HER2-targeted antibody and microtubule inhibitor conjugate indicated, as a single agent, for: the treatment of patients with HER2-positive, metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either: received prior therapy for metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy. ( 1.1 ) the adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment. ( 1.2 ) Select patients for therapy based on an FDA-approved companion diagnostic for KADCYLA [see Dosage and Administration (2.1) ]",
    "contraindications_original": "Do not substitute KADCYLA for or with trastuzumab. HER2 Testing: Perform using FDA-approved tests by laboratories with demonstrated proficiency. ( 2.1 ) For intravenous infusion only . Do not administer as an intravenous push or bolus. Do not use Dextrose (5%) solution. ( 2.4 ) The recommended dose of KADCYLA is 3.6 mg/kg given as an intravenous infusion every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity, or a total of 14 cycles for patients with EBC. Do not administer KADCYLA at doses greater than 3.6 mg/kg. ( 2.2 ) Management of adverse reactions (infusion-related reactions, hepatotoxicity, left ventricular cardiac dysfunction, thrombocytopenia, pulmonary toxicity or peripheral neuropathy) may require temporary interruption, dose reduction, or treatment discontinuation of KADCYLA. ( 2.3 )",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "KADCYLA",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_231601"
        }
    ]
}